caa a22 4500 445298782 CHVBK 20180317142550.0 cr unu---uuuuu 170323e20100601xx s 000 0 eng 10.1007/s11864-010-0120-6 doi (NATIONALLICENCE)springer-10.1007/s11864-010-0120-6 Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh [Elektronische Daten] [Joel Neal, Lecia Sequist] Opinion statement: The anaplastic lymphoma kinase (ALK) inhibitor crizotinib will become an integral addition to the treatment of patients with non-small cell lung cancer (NSCLC) harboring genetic ALK translocations. The insulin-like growth factor receptor (IGF-1R) monoclonal antibody figitumumab, while initially promising, appears to increase toxicity and death in combination with chemotherapy in the treatment of patients with NSCLC of squamous histology; therefore, clinical development of this class of agents will need to proceed with caution. The histone deacetylation (HDAC) inhibitor vorinostat did not demonstrate an improvement in overall survival (OS) compared with placebo in a large randomized trial, but other agents in this class may have greater selectivity and efficacy. Inhibitors of the hedgehog (Hh) signaling pathways have some early clinical promise in both NSCLC and small cell lung cancer (SCLC), and larger studies using these agents are eagerly anticipated. Springer Science+Business Media, LLC, 2010 Neal Joel Stanford Cancer Center, 875 Blake Wilbur Drive, 94305, Stanford, CA, USA aut Sequist Lecia Massachusetts General Hospital Cancer Center, 55 Fruit Street, 02114, Boston, MA, USA aut Current Treatment Options in Oncology Springer US; http://www.springer-ny.com 11/1-2(2010-06-01), 36-44 1527-2729 11:1-2<36 2010 11 11864 https://doi.org/10.1007/s11864-010-0120-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11864-010-0120-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Neal Joel Stanford Cancer Center, 875 Blake Wilbur Drive, 94305, Stanford, CA, USA aut NATIONALLICENCE 700 1- Sequist Lecia Massachusetts General Hospital Cancer Center, 55 Fruit Street, 02114, Boston, MA, USA aut NATIONALLICENCE 773 0- Current Treatment Options in Oncology Springer US; http://www.springer-ny.com 11/1-2(2010-06-01), 36-44 1527-2729 11:1-2<36 2010 11 11864 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer